Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani; Kamran Mansouri; Mohammad Sajad Emami Aleagha; Narges Moasefi; Niloofar Yavari; Seyed Kazem Shakouri; Sara Notararigo; Ali Shojaeian; Flemming Pociot; Reza Yarani

doi:10.3389/fimmu.2022.865782

Extracellular Vesicle Therapy for Type 1 Diabetes

Front Immunol. 2022 Apr 8:13:865782. doi: 10.3389/fimmu.2022.865782. eCollection 2022.

Authors

Affiliations

¹ Clinical Research Development Center, Taleghani and Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
² Medical Biology Research Center, Health Technology Institute, University of Medical Sciences, Kermanshah, Iran.
³ Medical Technology Research Center (MTRC), School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
⁴ Department of Cellular and Molecular Medicine, The Panum Institute, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁵ Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
⁶ Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain.
⁷ Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
⁸ Translational Type 1 Diabetes Research, Department of Clinical, Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
⁹ Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University School of Medicine, Palo Alto, CA, United States.

Abstract

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

Keywords: exosomes; extracellular vesicle; immunomodulation; therapy; type 1 diabetes; β-cell.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 1* / therapy
Extracellular Vesicles*
Humans
Immunomodulation
Insulin
Insulin-Secreting Cells*

Substances

Insulin